We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Tecan and Enigma Sign Global Manufacturing and Supply Agreement for Molecular Diagnostics Instruments
News

Tecan and Enigma Sign Global Manufacturing and Supply Agreement for Molecular Diagnostics Instruments

Tecan and Enigma Sign Global Manufacturing and Supply Agreement for Molecular Diagnostics Instruments
News

Tecan and Enigma Sign Global Manufacturing and Supply Agreement for Molecular Diagnostics Instruments

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tecan and Enigma Sign Global Manufacturing and Supply Agreement for Molecular Diagnostics Instruments"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Tecan Group and Enigma Diagnostics Limited announced the signing of a manufacturing and supply agreement for Enigma’s ML instruments.

Under the agreement, Tecan will industrialize and deliver commercially manufactured ML instruments for Enigma’s global market supplies for an initial five-year contract and will also manage the ML instrument’s supply chain. The first ML demonstration instruments have been delivered for Enigma’s GlaxoSmithKline delivery commitments for point-of-care molecular diagnostic influenza tests.

The launch of Enigma ML and supply of commercial series systems for its initial use to identify specific influenza virus strains is anticipated in Q4 2010, subject to successful clinical trials and regulatory approval. Enigma will also add additional tests for other areas such as infectious disease management to the ML system test menu in the future.

Financial details of the agreement were not disclosed.
Advertisement